Crohn’s Disease (CD) is a chronic inflammatory disease affecting as many as 700,000 Americans. CD most commonly affects the ileum (the end of the small intestine) and the beginning of the colon, but it may affect any part of the gastrointestinal (GI) tract. About a third of CD patients have disease only in the colon. CD can involve the full thickness of the intestinal wall and can skip sections of intestine. These characteristics make CD different from UC, which is limited to the colon, only affects the inner lining of the intestine, and is continuous.
CD’s symptoms may include frequent diarrhea, rectal bleeding, a sense of urgency to use the bathroom, and fatigue. CD sufferers may also experience fever, loss of appetite, weight loss, and other symptoms.
Treatment for CD can include the use of medication, alterations in diet and nutrition, and sometimes surgical procedures to repair or remove affected portions of your GI tract. Immunosuppressing medication is designed to decrease the body’s abnormal inflammatory response that causes your symptoms. Along with controlling and suppressing symptoms, medication can also be used to decrease the frequency of flare ups.
Asana plans to treat these patients similarly to how it will treat UC patients—by infusion of ECMH to the affected area using conventional delivery methods, where Asana believes it will create an environment favorable to healing.